Inozyme Pharma (NASDAQ:INZY) Posts Quarterly Earnings Results, Meets Expectations

Inozyme Pharma (NASDAQ:INZY) announced its quarterly earnings data on Monday. The company reported ($0.42) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.42), Zacks reports.

Inozyme Pharma Trading Down 3.7 %

NASDAQ:INZY opened at $1.11 on Monday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 7.68 and a current ratio of 7.68. The stock has a 50-day simple moving average of $1.62 and a 200-day simple moving average of $3.36. The stock has a market cap of $71.11 million, a P/E ratio of -0.71 and a beta of 1.32. Inozyme Pharma has a 1 year low of $1.04 and a 1 year high of $7.80.

Analyst Ratings Changes

A number of brokerages have issued reports on INZY. Wedbush restated an “outperform” rating and set a $12.00 target price on shares of Inozyme Pharma in a research report on Friday, January 10th. HC Wainwright lifted their price target on shares of Inozyme Pharma from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Friday, January 10th. Piper Sandler dropped their price objective on Inozyme Pharma from $43.00 to $30.00 and set an “overweight” rating on the stock in a research note on Monday, January 13th. Raymond James started coverage on shares of Inozyme Pharma in a report on Thursday, December 12th. They set an “outperform” rating and a $26.00 price objective on the stock. Finally, Wells Fargo & Company lowered their target price on shares of Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, January 13th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $18.33.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.